Quantum BioPharma (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial

Austin, Texas, October 6th, 2026, FinanceWire

Quantum BioPharma (NASDAQ: QNTM) entered into a Study Start-Up Agreement (“SUA”) with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-21-302 (“Lucid-MS”) for multiple sclerosis (“MS”). The agreement initiates formal study start-up activities following FDA clearance to proceed with the trial. Thermo Fisher will support study start-up and related clinical research services through its PPD(TM) Clinical Research Business.

Quantum BioPharma said the randomized, double-blind, placebo-controlled Phase 2 trial will evaluate the efficacy, safety and tolerability of Lucid-MS in people with progressive forms of MS using clinical and radiological endpoints. Lucid-MS is an investigational, first-in-class New Chemical Entity designed to provide neuroprotection by inhibiting demyelination through targeting protein arginine deiminase 2 (“PAD2”), an enzyme implicated in myelin degradation.

To view the full press release, visit https://ibn.fm/CZH9U

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

Corporate Communications

IBN

Austin, Texas

www.IBN.ai

512.354.7000 Office

Editor@IBN.ai